Skip to main content
    A

    argenx NV ADR (ARGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $846.27
    +27.97 (+3.42%)

    Market Cap: $50.85B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(23/37)
    Avg Surprise
    +65.42%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-9.78
    Range$-27.83 - $8.28
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$6.94-240.8%
    60d ago$7.33-233.4%
    30d ago$-27.83+64.9%
    7d ago$-27.83+64.9%
    Current$-9.78
    Revenue Consensus
    $1.6B
    Range$1.6B - $1.6B
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$18.06
    Range$-5.97 - $27.46
    4 analysts
    Revenue Consensus
    $2.1B
    Range$2.0B - $2.2B
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$18.06---
    Sep 26EST
    		-$-9.78---
    Jun 26
    Reported Jul 23
    		$7.32$6.13+19.41%Beat+95.7%
    Mar 26
    Reported May 7
    		$5.52$4.92+12.20%Beat+114.0%
    Dec 25
    Reported Feb 26
    		$8.02$6.24+28.53%Beat+1025.6%
    Sep 25
    Reported Oct 30
    		$5.18$4.16+24.52%Beat+272.7%
    Jun 25
    Reported Jul 31
    		$3.74$3.02+23.84%Beat+731.1%
    Mar 25
    Reported May 8
    		$2.58$2.31+11.69%Beat+348.1%
    Dec 24
    Reported Mar 31
    		$0.71N/A-58.04%Miss+142.4%
    Sep 24
    Reported Oct 31
    		$1.39$0.06+2216.67%Beat+211.2%
    Jun 24
    Reported Jul 25
    		$0.45N/A+142.06%Beat+126.6%
    Mar 24
    Reported May 9
    		$-1.04$-0.87-19.54%Miss-100.0%
    Dec 23
    Reported Feb 29
    		$-1.68$-1.70+1.18%Beat-140.0%
    Sep 23
    Reported Oct 31
    		$-1.25$-1.45+13.79%Beat+70.7%
    Jun 23
    Reported Jul 27
    		$-1.69$-1.86+9.14%Beat+55.6%
    Mar 23
    Reported May 4
    		$-0.52N/A+77.19%Beat+88.1%
    Dec 22
    Reported Mar 2
    		$-0.70$-0.70+0.00%Beat+86.2%
    Sep 22
    Reported Oct 27
    		$-4.26$-3.58-18.99%Miss-68.4%
    Jun 22
    Reported Jul 28
    		$-3.81$-4.72+19.28%Beat-292.4%
    Mar 22
    Reported May 5
    		$-4.36$-5.10+14.51%Beat-438.3%
    Dec 21
    Reported Mar 3
    		$-5.06$-4.81-5.20%Miss-43.3%
    Sep 21
    Reported Oct 28
    		$-2.53$-4.58+44.76%Beat+36.9%
    Jun 21
    Reported Jul 29
    		$1.98$-3.23+161.30%Beat+158.6%
    Mar 21
    Reported May 14
    		$-0.81N/A+71.38%Beat+59.9%
    Dec 20
    Reported Mar 4
    		$-3.53$-2.64-33.71%Miss-48.9%
    Sep 20
    Reported Oct 22
    		$-4.01$-2.78-44.24%Miss-449.3%
    Jun 20
    Reported Jul 31
    		$-3.38$-2.51-34.66%Miss-119.5%
    Mar 20
    Reported May 14
    		$-2.02$-1.79-12.85%Miss-201.5%
    Dec 19
    Reported Feb 29
    		$-2.37$-1.38-71.74%Miss-163.3%
    Sep 19
    Reported Oct 24
    		$-0.73$-1.05+30.48%Beat-10.6%
    Jun 19
    Reported Aug 1
    		$-1.54$-0.88-75.00%Miss-2100.0%
    Mar 19
    Reported May 9
    		$-0.67$-0.77+12.99%Beat+17.3%
    Dec 18
    Reported Feb 28
    		$-0.90$-0.65-38.46%Miss-119.5%
    Sep 18
    Reported Oct 25
    		$-0.66$-0.77+14.29%Beat-50.0%
    Jun 18
    Reported Aug 2
    		$-0.07N/A+85.42%Beat-800.0%
    Mar 18
    Reported May 9
    		$-0.81$-0.22-268.18%Miss-83.8%
    Dec 17
    Reported Mar 1
    		$-0.41$-0.35-17.14%Miss+16.8%
    Sep 17
    Reported Oct 26
    		$-0.44$-0.37-18.92%Miss-
    Jun 17
    Reported Aug 24
    		$0.01N/A+102.70%Beat-
    Mar 17
    Reported May 2
    		$-0.44N/AN/ABeat-
    Dec 16
    Reported Mar 15
    		$-0.49N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio32.50EV/EBITDAN/A
    Price/FCF33.46xFCF Yield2.99%
    Profitability
    Profit Margin32.30%Operating Margin32.00%
    ROE23.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage531.64x
    Current Ratio5.12xQuick Ratio4.89x
    Trading Statistics
    Beta-0.04Avg Volume416.65K
    52-Week High$1072.7552-Week Low$661.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$861.42
    SMA 20$913.09
    SMA 50$953.99
    SMA 200$851.47
    EMA 10$858.59
    EMA 20$895.84
    EMA 50$924.09
    EMA 200$865.35

    MACD

    Line: -40.95Signal: -29.38Hist: -11.57

    ADX

    ADX: 31.6+DI: 18.0-DI: 37.9

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down80.0
    PSAR$916.65

    Bollinger Bands

    Upper Band$1044.73
    Lower Band$781.45
    %B Position2883%(Upper)
    Band Width0.25

    RSI (14-Day)

    Neutral
    36.4

    Momentum Oscillators

    Stoch %K18.3
    Stoch %D14.6
    Williams %R-69.1
    ROC (10d)-9.6%
    Momentum-89.73
    CCI (20d)-78.8
    MFI (14d)35.7

    Volatility Measures

    ATR (14d)$31.53(3.7%)
    StdDev (20d)65.82
    Hist Vol48.5%(High)

    Volume Flow

    VWAP$847.87
    OBV1.8M
    AD Line532.4K
    CMF (20d)0.001

    Volume Metrics

    Avg Vol (20d)436.0K
    Vol Ratio1.2x
    VWMA (20d)$884.30

    Pivot Points

    R3$867.05
    R2$851.18
    R1$834.74
    Pivot Point$818.87
    S1$802.43
    S2$786.56
    S3$770.12

    Advanced Oscillators

    TSI-35.55
    Ultimate Osc36.4
    KST-118.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.82B$1.30B$3.21B$1.13B$947.96M$790.68M$1.35B$573.24M$901.94M$401.00M$757.68M$329.79M
    Cost of Revenue$279.27M$121.00M$339.92M$109.43M$110.75M$80.81M$664.90M$59.07M$43.18M$43.18M$573.60M$36.00M
    Gross Profit$2.54B$1.18B$2.87B$1.02B$837.21M$709.88M$681.37M$514.16M$425.25M$357.82M$184.07M$293.79M
    Operating Expenses$1.69B$904.00M$2.01B$776.99M$633.37M$568.63M$562.71M$499.98M$451.24M$451.24M$796.72M$374.38M
    R&D$486.00M$443.00M$443.00M$355.65M$327.70M$309.07M$297.23M$235.94M$446.79M$224.97M$396.66M$191.75M
    SG&A$532.52M$355.00M$422.54M$336.29M$422.91M$276.25M$256.66M$277.70M$341.35M$236.00M$198.61M$191.93M
    Operating Income$846.83M$394.00M$850.77M$349.97M$203.84M$141.25M$117.23M$14.19M$-138,882,000$-93,421,000$-219,212,000$-80,588,000
    Interest Income$48.00M$44.00M$44.87M$42.70M$38.40M$37.12M$20.33M$40.59M$38.93M$38.90M$25.88M$30.05M
    Interest Expense$2.00M$1.00M$1.00M$993,000$1.13M$1.14M$704,000$676,000$572,000$512,000$278,000$231,000
    Income Before Tax$958.94M$426.00M$991.71M$386.05M$286.90M$202.36M$174.53M$88.02M$-89,353,000$-74,350,000$-144,457,000$-83,279,000
    Income Tax Expense$119.12M$0$-54,969,000$0$41.54M$32.89M$33.00M$-3,386,000$-56,822,000$-12,753,000$27.36M$-10,637,000
    Net Income$838.82M$366.00M$1.05B$344.26M$245.36M$169.47M$865.57M$91.41M$-32,531,000$-61,597,000$-155,629,000$-72,642,000
    EBITDA$863.85M$427.00M$1.01B$387.05M$301.39M$203.50M$126.61M$97.59M$-21,471,000$-65,228,465$-38,139,957$20.42M
    EBIT$846.83M$427.00M$994.66M$387.05M$288.02MN/A$117.72M$88.70M$-30,081,000$-73,838,000$-141,622,788$-83,048,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARGX

    News

    Oppenheimer cuts target to USD 1,038 for Argenx stock

    Oppenheimer has cut its price target for Argenx (NL0010832176) stock to USD 1,038 from USD 1,100, while maintaining an "outperform" rating. This adjustment follows Argenx's strong second-quarter revenue of USD 1.54...

    ad-hoc-news.de•10/14/26•Neutral

    Argenx halts UNITY study. Argenx stock trades 1.18 percent higher

    Argenx has stopped its Phase 3 UNITY study for Sjogren's disease due to futility after an interim analysis, but its stock still rose by 1.18 percent. This setback is partially offset by positive Phase 2 results for FB102...

    ad-hoc-news.de•10/12/26•Neutral

    Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurocrine (NBIX)

    Analysts are showing bullish sentiment towards healthcare stocks Argenx Se (ARGX) and Neurocrine (NBIX). UBS analyst Xian Deng maintained a Buy rating on Argenx Se with a $1400 price target...

    The Globe and Mail•10/11/26•Bullish

    Wells Fargo Remains a Buy on Argenx Se (ARGX)

    Wells Fargo analyst Derek Archila maintained a Buy rating on Argenx Se (ARGX) with a price target of $1,355.00. Argenx Se has a Strong Buy analyst consensus rating with an average price target of $1,179.42...

    The Globe and Mail•10/10/26•Somewhat-Bearish

    $100 Invested In argenx 5 Years Ago Would Be Worth This Much Today

    argenx (NASDAQ: ARGX) has significantly outperformed the market over the last five years, achieving an average annual return of 22.71%. An initial investment of $100 in ARGX five years ago would now be worth $279.28....

    Benzinga•10/9/26•Bullish

    ARGX Valuation and Fair Value

    P/E
    32.5x
    Forward P/E
    25.9x
    P/FCF
    33.5x
    PEG
    1.1x
    P/B
    6.5x
    See GNG's fair value

    ARGX Profitability: Margins, ROIC and FCF

    Gross margin
    89.9%
    Operating margin
    32.0%
    Net margin
    32.3%
    ROE
    23.6%
    FCF margin
    19.3%
    FCF yield
    3.0%

    ARGX Competitors

    CompanyTicker
    Humana IncHUM
    Edwards Lifesciences CorpEW
    Becton Dickinson and CompanyBDX
    Agilent Technologies IncA
    Natera IncNTRA
    Veeva Systems Inc Class AVEEV
    Cardinal Health IncCAH
    Teva Pharma Industries Ltd ADRTEVA

    Sector: Healthcare

    ARGX Analyst Ratings

    Consensus
    Buy
    Analysts
    25
    Strong Buy
    7
    Buy
    15
    Hold
    3
    Sell
    0
    Strong Sell
    0

    ARGX Bull Case vs Bear Case

    Bull case

    • ARGX converts 19.3% of revenue into free cash flow.
    • ARGX has a 32.3% net profit margin.
    • ARGX beat EPS estimates in 87.5% of its last 8 reported quarters.

    ARGX Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    284.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-9.78
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About ARGX

    Does ARGX pay dividends?

    argenx NV ADR (ARGX) does not currently pay a regular dividend.

    What is ARGX's P/E ratio?

    argenx NV ADR has a price-to-earnings (P/E) ratio of 32.50.

    What is ARGX's market cap?

    argenx NV ADR (ARGX) has a market capitalization of $50.85B with a current stock price of $846.27.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In